Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
E-pub ahead of print

Beta-blocker use and acute exacerbations of COPD following myocardial infarction: a Danish nationwide cohort study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Acute exacerbations of chronic obstructive pulmonary disease: in search of diagnostic biomarkers and treatable traits

    Research output: Contribution to journalReviewResearchpeer-review

  2. Supervised pulmonary tele-rehabilitation versus pulmonary rehabilitation in severe COPD: a randomised multicentre trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. One-year outcomes in a multicentre cohort study of incident rare diffuse parenchymal lung disease in children (ChILD)

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. β2-Adrenergic genotypes and risk of severe exacerbations in COPD: a prospective cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Midlife cardiorespiratory fitness and the long-term risk of chronic obstructive pulmonary disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Association between biomarkers and COVID-19 severity and mortality: a nationwide Danish cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Risk Factors for Morbidity and Mortality Following Hospitalization for Pericarditis

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

INTRODUCTION: Patients with chronic obstructive pulmonary disease (COPD) are undertreated with beta-blockers following myocardial infarction (MI), possibly due to fear for acute exacerbations of COPD (AECOPD). Is beta-blocker use associated with increased risk of AECOPD in patients following first-time MI?

METHODS: Danish nationwide study of patients with COPD following hospitalisation for MI from 2003 to 2015. Multivariable, time-dependent Cox regression accounting for varying beta-blocker use based on claimed prescriptions during up to 13 years of follow-up.

RESULTS: A total of 10 884 patients with COPD were discharged after first-time MI. The 1-year rate of AECOPD was 35%, and 65% used beta-blockers at 1 year. Beta-blocker use was associated with a lower risk of AECOPD (multivariable-adjusted HR 0.78, 95% CI 0.74-0.83). This association was independent of the type of MI (HR 0.70, 95% CI 0.59-0.83 in ST-elevation MI (STEMI) and HR 0.80, 95% CI 0.75-0.84 in non-STEMI), presence or absence of heart failure (HR 0.82, 95% CI 0.74-0.90 and HR 0.77, 95% CI 0.72-0.82, respectively), beta-blocker dosage and type, as well as exacerbation severity. Results were similar in 1118 patients with full data on COPD severity and symptom burden (median forced expiratory volume in 1 s as percentage of predicted was 46 and majority had moderate dyspnoea), and in 1358 patients with severe COPD and frequent AECOPD with a high 1-year rate of AECOPD of 70%.

DISCUSSION: Beta-blocker use was not associated with increased risk of AECOPD following MI. This finding was independent of COPD severity, symptom burden and exacerbation history, and supports the safety of beta-blockers in patients with COPD, including high-risk patients with severe disease.

Original languageEnglish
JournalThorax
ISSN0040-6376
DOIs
Publication statusE-pub ahead of print - 20 Aug 2020

ID: 61014520